Monoclonal antibodies, such as trastuzumab, that bind to HER2 proteins can be used along with chemotherapy to treat patients with HER2-overexpressing breast cancer with metastases to organs outside of the breast. This evidence concerns the gene ERBB2 and breast carcinoma.